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ABSTRACT
Objectives: To examine how general practitioners
(GPs) in the UK and GPs in Australia explain their
prostate-specific antigen (PSA) testing practices and to
illuminate how these explanations are similar and how
they are different.
Design: A grounded theory study.
Setting: Primary care practices in Australia and the UK.
Participants: 69 GPs in Australia (n=40) and the UK
(n=29). We included GPs of varying ages, sex, clinical
experience and patient populations. All GPs interested in
participating in the study were included.
Results: GPs’ accounts revealed fundamental
differences in whether and how prostate cancer
screening occurred in their practice and in the broader
context within which they operate. The history of
prostate screening policy, organisational structures and
funding models appeared to drive more prostate
screening in Australia and less in the UK. In Australia,
screening processes and decisions were mostly at the
discretion of individual clinicians, and varied
considerably, whereas the accounts of UK GPs clearly
reflected a consistent, organisationally embedded
approach based on local evidence-based
recommendations to discourage screening.
Conclusions: The GP accounts suggested that
healthcare systems, including historical and current
organisational and funding structures and rules,
collectively contribute to how and why clinicians use the
PSA test and play a significant role in creating the
mindlines that GPs employ in their clinic. Australia’s
recently released consensus guidelines may support
more streamlined and consistent care. However, if GP
mindlines and thus routine practice in Australia are to
shift, to ultimately reduce unnecessary or harmful
prostate screening, it is likely that other important
drivers at all levels of the screening process will need to
be addressed.
BACKGROUND
Prostate-speciﬁc antigen (PSA) testing of
asymptomatic men for prostate cancer risk is
a contested issue internationally. In this
paper, ‘asymptomatic’ will refer to those men
attending clinical practice with no prior indi-
cations associated with prostatic disease. This
is in contrast to the detection of prostate
cancer in symptomatic men: men who have
symptoms that could be related to locally
advanced or metastatic prostate cancer such
as frequency of urination, new onset bone
pain and/or neurological symptoms involv-
ing the lower extremities.1 PSA testing of
asymptomatic men is not recommended as a
population-screening programme in Australia
or the UK, the two countries on which our
analysis focuses.
Prostate cancer incidence varies more than
25-fold worldwide. Incidence ﬁgures, which
incorporate both life-saving diagnoses and
Strengths and limitations of this study
▪ The published literature about prostate cancer
screening in general practice is replete with
quantitative studies: They have identified clinician
and patient demographics associated with more
or less screening, and have analysed rates of
screening and frequency of discussions about
prostate-specific antigen (PSA) testing. Our
research is complementary to existing quantita-
tive findings: We asked how PSA testing of
asymptomatic men occurs in clinical practice,
from the general practitioner (GP) perspective.
▪ This study applied grounded theory methodology
to explore how clinicians describe their prostate
screening practice, and relate these to points of
variation in the respective healthcare systems.
Grounded theory is a suitable approach for the
investigation of complex multifaceted processes
(like PSA screening) occurring in context.
▪ We interviewed a large number of highly inform-
ative participants (GPs) in Australia and the UK
with diverse opinions and approaches.
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overdiagnosed cancers,2 vary between Australia, where inci-
dence is 115.22 cases per 100 000 population, and the UK,
where incidence is 73.19 per 100 000. Despite this differ-
ence in reported incidence, the two countries have roughly
equivalent prostate cancer mortality ﬁgures: 12.88 and
13.07 per 100 000, respectively.3 There are many reasons
for variation in incidence and mortality rates, which could
be due to underlying differences in prostate cancer risk
and population age structures, men presenting for testing,
access and availability of treatment options, cancer coding
and registration and diagnostic processes (such as availabil-
ity of PSA testing and improved diagnosis).
An important factor inﬂuencing reported prostate
cancer incidence in a population is PSA testing rates:
higher testing rates produce higher incidence. Testing
rates may be inﬂuenced by differences in professional
and organisational policies, media, cultural beliefs and
values. Annual PSA testing rates of asymptomatic men in
general practice are difﬁcult to ascertain. The data col-
lected often do not distinguish men who have had a
PSA for prostate cancer screening from those in whom
established disease is being monitored.
Clinical practice in the UK and Australia is grounded
in the same evidence base and international literature,
yet the two jurisdictions have notably different rates of
PSA testing. In the UK, a study in six English cities
reported the annual practice-based PSA testing rate for
2007 (in men aged 45–89 years) to be 6.2%.4 A more
recent study analysed data from patient electronic
records in primary care for men aged 45–84 years. It
reported that for every 100 men enrolled with a general
practitioner (GP) for one year, 5.03 (asymptomatic
men) were tested in 2010, and the rate increased by 8%
in 2011 to 5.45 per 100.5 Note that the data this analysis
was based on represent only 5% of the population in
England and may not be representative of all practices.
Analysis of Medicare Australia’s Medical Beneﬁts
Scheme records suggests that each year at least 20% of
men aged 45–74 years have a PSA test, presumably for
the purpose of early diagnosis of prostate cancer.6 This
number underestimates the actual number of PSA tests
performed, by up to 40%.7 The prevalence of PSA
testing in men over 50 years in Australia was reported at
63% in 2003; that is, 63% of men >50 years had ever had
a PSA test.8 This proportion is likely to have risen since.9
This raises questions about how practice in the two jur-
isdictions, while drawing on the same evidence base,
could be so markedly different. In table 1, we set out
some important differences in the organisation and
funding of primary healthcare between Australia and
the UK, including subtle variance in the advice offered
to GPs from expert authorities in relation to how actively
physicians should offer testing. Any or all of these differ-
ences conceivably inﬂuence testing rates.
Here, we report on a comparative qualitative study of
Australian and UK GPs’ current approaches to, and rea-
soning about, PSA testing of asymptomatic men to
address the following questions:
▸ How do GPs in the UK and GPs in Australia explain
their PSA testing practices?
▸ How are these explanations similar and different?
Our analysis draws on Gabbay and le May’s14 concept
of ‘mindlines’, which they developed to explain how GPs
use research evidence in practice. They describe mind-
lines as ‘collectively reinforced, internalised, tacit guide-
lines’,15 mainly grown and reﬁned via training,
experience and interaction with trusted sources, and
mediated by features of primary care organisations,
including their ethos and ﬁnancial and structural ele-
ments. Their mindlines theory makes a valuable contri-
bution to the evidence-based medicine (EBM) and
knowledge translation literatures because the theory
considers the inﬂuence of local context on GP adhe-
rence and use of formal knowledge like guidelines. We
use our analysis of data collected from GPs practising in
Australia and the UK to extend Gabbay and le May’s
theory of mindlines.
METHODS
Design
We applied the well-established, systematic qualitative
research methodology of grounded theory.15 Grounded
theory is a method of conducting qualitative research
that focuses on creating conceptual frameworks or the-
ories through building inductive analysis from the
data.16 Grounded theorists are led by the experiences of
the people in their inquiry and the substantive theories
they develop closely reﬂect what those people experi-
ence and do. Speciﬁc methods of data collection and
analysis are used to identify patterns in the research
data. The twin foundations of grounded theory are the
processes of constant comparison (a simultaneous and
concurrent process of coding and analysis) and theoret-
ical sampling (sampling with the aim of developing the
properties of a developing idea or theory). These
methods together guide the systematic development of
emerging theory, and ensure ﬁndings remain ﬁrmly
grounded in the collected data. All study authors have
been formally trained in the methods described; SC has
particular expertise in grounded theory methodology.
Participants and setting
We purposively recruited a sample of 69 GPs (Australia,
n=40; the UK, n=29) for this study. In Australia, we
advertised via the newsletters and email lists of GP orga-
nisations (Medicare Locals) in Sydney, and in mass and
social media, and in medical journals. As analysis and
sampling evolved, we invited additional rural and inter-
state GPs to answer speciﬁc analytical questions; for
example, the inﬂuence of GP proximity to specialist ser-
vices. Rural GPs were accessed by phoning practice man-
agers, through colleagues, and advertising with rural
Medicare Locals.17 When we encountered GPs whose
routine care was divergent from previously interviewed
GP norms, we invited more GPs from that practice to
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Table 1 A comparison of Australian and UK health systems and PSA testing context
Australia The UK
How is primary
healthcare provided?
The Australian Medicare system is
predominantly based around private practice
and fee-for-service funding, that is, private
practitioners in independent businesses are paid
for each instance of service, mainly using public
funds through the MBS, sometimes
supplemented by patient copayments.
Some GPs bulk bill, that is, GPs charge the
Government (Medicare) directly for any medical
service that their patient receives. In these
practices, GPs receive the Medicare rebate (a
fixed sum for each type of service) as payment,
and patients pay nothing. There is considerable
geographical variation in bulk billing practice
depending on where the GP is based (less in
more affluent areas and in rural, regional and
remote areas,10–12 where there is a greater
shortage of doctors and healthcare services).
There are standards but GPs are mostly free to
set their own fees for consultations and
procedures. Some charge substantially more
than the value of the Medicare rebate.
Australians can consult any GP they choose,
including seeing multiple GPs in multiple
practices.
The countries of the UK have centralised health
systems—the NHS. General practices mostly
operate as independent businesses managed
by GPs delivering care under contract to the
NHS and free to the patient at point of use.
GPs receive some payment on a capitation
basis (practices receive a fixed amount to
manage a set of potential patients).
There is virtually no fee for service element, but
some of the money practices receive from the
NHS is dependent on them supplying evidence
that certain quality standards have been met
(eg, that at least n% of people with a diagnosis
of x have received intervention y).
Almost all residents in the UK are registered to
a GP practice near their usual home, and will
consult GPs within that practice.
Are GPs advised to
offer PSA testing?
RACGP advises its members not to raise the
issue of PSA testing with patients, but if men
ask, to fully inform them about the potential
benefits, risks and uncertainties.
USANZ advises for men at average risk of
prostate cancer, who have been informed of the
benefits and harms of testing and who decide to
undergo regular testing for prostate cancer, offer
PSA testing every 2 years from 50–69 years,
and offer further investigation if total PSA is
greater than 3.0 ng/mL.
Universal screening for prostate cancer is not
recommended; however, PSA testing can be
provided at patient request (UK National
Screening Committee).
EAU advises that informed men requesting an
early diagnosis should be given a PSA test and
undergo a DRE. A risk-adapted strategy might
be considered based on the initial PSA level.
How should men be
tested (if they choose to
be tested)?
GPs advised to discuss the pros and cons of
testing with eligible men.
2012 RACGP Red Book guidance advises GPs
to perform PSA and DRE when a patient
chooses screening, whereas Australian NHMRC
guidelines do not recommend DRE for
asymptomatic men in the primary care setting.
USANZ suggests that GPs confident in
performing DRE are still encouraged to do so.
GPs advised to discuss the pros and cons of
testing with eligible men.
DRE is not recommended as a screening test in
asymptomatic men in the UK (NHS PCRMP).
Men aged >50 years who request a PSA test
can access the NHS PCRMP, an informed
choice programme introduced by the
Government in 2002 to ensure that men
concerned about prostate cancer receive clear
and balanced information. The PCRMP
provides GPs with information to counsel any
man who asks about PSA testing. It is an
English initiative, but Wales, Scotland and
Northern Ireland have adopted the same
approach and use the same materials
Is the PSA test funded? The Australian Government has subsidised PSA
tests for men 50 years and over since 1989
through the MBS.13
PSA testing can be provided free on the NHS
for men over 50 years on the condition they
have made an ‘informed choice’ following a GP
consultation.
DRE, digital rectal examination; EAU, European Association of Urology; GP, general practitioner; MBS, Medicare Benefits Schedule; NHMRC,
National Health and Medical Research Council; NHS, National Health Service; NHS PCRMP, National Health Service Prostate Cancer Risk
Management Programme; PSA, prostate-specific antigen (test); RACGP, Royal Australian College of General Practitioners; USANZ,
Urological Society of Australia and New Zealand.
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attempt to distinguish between personal and institu-
tional inﬂuences on their practice.
We recruited 29 GPs throughout England (n=23),
Scotland (n=5) and Wales (n=1) to explore PSA testing
reasoning and practice in a jurisdiction with compara-
tively lower rates of prostate cancer screening than
Australia. The initial sample of GPs responded to an
invitation distributed by academic colleagues through
professional networks. We then broadened the sample
by advertising via email to members of the Royal College
of General Practitioners (RCGP), primary healthcare
departments, university academic departments and
general practice and research mail lists. We also adver-
tised via newsletter including the Society for Academic
Primary Care and RCGP Scotland’s eBulletin.
GPs were invited to contact KP if they were interested
and willing to participate. An information sheet outlin-
ing the research project was emailed to all respondents.
Participants were of varying ages, clinical experience,
sex and patient populations: all GPs who expressed
interest in participating were included. GPs were com-
pensated for their time.
Interviews/data collection
We generated data via in-depth interviews. The semi-
structured interview schedule covered a broad range of
topics, including GPs’ recent clinical encounters involv-
ing PSA testing decisions, communicating information
about PSA testing to patients, screening pathways for
PSA and overdiagnosis of prostate cancer. The schedule
was modiﬁed between interviews based on the develop-
ing analysis to enrich the data available to answer our
research questions. All GPs were asked to think back to
their most recent consultation involving a discussion
about PSA testing or to describe a typical consultation
where the topic was raised. The aim of this approach
was to open the discussion about, and provide context
for, conversations about PSA testing and to use as a plat-
form to guide prompts and to focus subsequent
questions.
Interviews took place between March 2013 and June
2014 (Australian GPs) and between September and
December 2014 (UK GPs). We continued to interview
GPs until we judged we had reached theoretical satur-
ation, that is, the point at which gathering more data
ceases to yield any further insights about the emerging
grounded theory. All interviews were conducted by KP,
primarily by telephone or Skype, and ranged in duration
from 18 to 70 min. All interviews were audio-recorded,
and were transcribed verbatim.
Data coding and analysis
The analysis was led by KP, who coded the transcripts
and wrote detailed memos which were reviewed and dis-
cussed by the authors in analysis meetings. A subset of
transcripts was read and coded by three authors inde-
pendently; this coding was compared and discussed to
inform the development of the central concepts in the
study. All concepts were derived directly from the data.
Transcripts were not returned to participants for
comment; all participants will receive a written summary
of the research ﬁndings on study completion.
Role of the funding source
This study was funded by Australia’s National Health
and Medical Research Council (NHMRC) through a
peer-reviewed competitive process. The funder had no
role in the design, conduct or reporting of the study.
RESULTS
We identiﬁed notable differences in GPs’ explanations
of PSA testing in their individual practices, and within
GPs’ descriptions about the conditions of the respective
health systems in Australia and the UK. One striking dif-
ference was that Australian GPs reported that they fre-
quently spoke with asymptomatic men about being
screened for prostate cancer, while UK GPs reported
that they did this rarely. Another was that the process by
which PSA testing occurred in each country appeared to
be quite different. We explore below potential explana-
tions for these differences.
How did UK and Australian GPs’ descriptions of their
practices differ?
Testing as an exception versus testing as routine
GPs’ descriptions of a ‘typical’ consultation with a
PSA-age man were very different in the two jurisdictions.
Most GPs practising in the UK commented that PSA
testing is quite uncommon and is certainly not consid-
ered routine practice. GPs said it would be ‘rare’ or
‘unusual’ for asymptomatic men to request PSA testing.
UK GPs noted they may only receive a few PSA requests
a year and some could not recall an example to refer to
in the interview. The idea that a GP might introduce
PSA testing as an issue for consideration for an other-
wise healthy man was seen as strange; “if they’re coming in
with other issues, then we wouldn’t say, oh by the way, you
don’t want a PSA test, do you? That just wouldn’t happen”
(GP1). UK GPs tended not to order the test unless spe-
ciﬁcally asked to do so, and some would “work quite hard
to talk [asymptomatic] people out of it” (GP12).
In stark contrast, many Australian GPs talked about
PSA testing as an everyday, usual part of consultations,
and all reported that they commonly received requests
for the test. Some said that on a typical day, they
ordered several PSA tests for asymptomatic men. A sig-
niﬁcant proportion of the Australian GPs interviewed
said that they might also raise PSA testing with a patient,
unprompted. They reported that they would suggest
testing because of a man’s age, or raise it in the context
of a health check. To quote one GP: “people are used to
sort of being screened…so we’re tacking this onto the discussion
basically” (AGP21). Some GPs said their patients “don’t
get a chance” to initiate a discussion about PSA testing
before the GP “talks them into it there and then” (AGP29).
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How PSA testing occurred: immediate testing versus a
cooling-off period with extra information
The main difference between UK and Australian GPs’
descriptions of how PSA testing occurred was that for
Australian men, a decision about testing, and the order-
ing of a PSA test, was likely to occur in the consultation
in which it was ﬁrst raised. In contrast UK GPs described
a two-step process, with a ‘cooling-off’ period between
discussion and testing (if testing occurred at all).
UK GPs consistently reported the use of written informa-
tion leaﬂets (mostly from www.patient.co.uk). They would
give these to men who asked about PSA testing to take
away and read to help them decide whether they wanted
to be tested. GPs said that verbal discussions within the
consultations were relatively brief because of the compre-
hensiveness of this resource. GPs noted that having a
built-in ‘cooling-off period’ effectively (1) demonstrates
that PSA testing is not something to rush into, and (2)
allows patients to absorb the information in the leaﬂet
before making a decision. A number of GPs said that men
decided not to have PSA testing after receiving the infor-
mation, “but whether that is because they’ve really understood the
information or whether they’ve just picked up on the vibe, I
couldn’t really give you a good answer on that” (GP15).
GPs in Australia did not commonly report providing
written information to their patients; they predomin-
antly described having a verbal discussion only. Some
GPs described engaging men in quite a detailed explan-
ation about PSA testing, while other GPs said their dis-
cussion was “very, very brief” (AGP14). One GP, for
example, reported: ‘I give them next to none [information].
I say ‘Do you want to ﬁnd out if you’ve got prostate cancer?”’
(AGP9). Sometimes there was no discussion prior to
testing. Other GPs apparently tried—and said they
would sometimes succeed—to counsel men out of
having a PSA test, reporting, for example, that “nine out
of ten will choose not to have the test after appropriate explan-
ation” (AGP23). These examples illustrate the consider-
able diversity of practice in Australia compared with the
relative consistency of practice in the UK.
What practice conditions did GPs report that might help
explain differences in practice?
We explored GPs’ descriptions of training, structures and
availability of resources, which served as anchors for their
use of PSA testing as a screening tool. We outlined the simi-
larities and differences we observed in UK and Australian
GPs’ accounts of the conditions under which they prac-
ticed. Table 2 is a representation of the ‘system’: not just
the health system but the broader social and funding struc-
tures, comprising several interacting components.
Figure 1 illustrates the direction in which the system
factors presented in table 2 potentially inﬂuence pros-
tate screening: towards more PSA testing or towards less
PSA testing, and including those system factors with no
reported impact on testing rates.
Here, we present three overarching themes we subse-
quently identiﬁed as underlying and likely contributing
to the variation evident in the GP’s accounts: (1) history
of PSA testing policy, (2) healthcare structures and
incentives and (3) GP’s preferred source of knowledge.
The history of PSA testing policy in the two countries is an
important distinguishing factor
A number of GPs in the UK reported the long-standing
consistency of a central authoritative position discour-
aging prostate cancer screening. The policy could be
summarised as ‘don’t raise it, and inform if asked’. From
the mid-1990s all GPs in the UK were sent relatively
easy-to-read summaries of the evidence together with
written information to hand out to men who asked
about the PSA test.18 Dissemination of similar informa-
tion has been used continuously since.
In contrast, in the Australian context, some GPs
recalled the positive publicity that accompanied PSA
testing when it was ﬁrst introduced. Online documents
indicate that, simultaneously, some Australian authorities
actively encouraged and promoted PSA testing of asymp-
tomatic men, while other ofﬁcial guidelines, released as
early as 1995, recommended against prostate screen-
ing.19 20 As shown in table 2, Australian GPs reported
that the guideline environment is challenging to navi-
gate, making it difﬁcult for GPs to ﬁnd consistent and
centrally issued directive advice.
The early messaging to GPs seems to have had long-
lasting implications. GPs in both countries commented
on the tendency to continue practising in the manner
in which they began. One UK GP explained, “it’s quite
difﬁcult to change your practice. I think if you’re a GP who’s
never been doing the PSA test then it’s easier for you to carry on
not doing them” (GP9). An Australian GP said,
I guess we learn from our initial experiences and it’s very
hard to change your initial thoughts on a particular test.
So my initial understanding was it’s an amazing test, that
it should be done, that it’s very useful, that you’re almost
neglectful not to do it… the initial thing was PSA is
useful and that has basically stuck in my head, that PSA
testing is useful. (AGP1)
How healthcare structures and incentives drive practice
The clinicians’ accounts clearly reﬂected the known dif-
ferences in healthcare payment models between the two
locations. In Australia, GPs are paid fee-for-service—a
scheme dependent on the quantity of instances of
patient care—thus more patients, procedures and
appointments generate greater income for GPs. One GP
commented on the implications of fee-for-service,
If I went around having my 10 minute discussion with all
my patients about why not to do PSA testing, I will make
less money than [a GP] who does the 30 second—here
Jack, that’s a good idea, here, have the PSA test, we’ll see
you in a fortnight to check the result…one of the conse-
quences of the current health system is that it feeds itself
to making more diagnoses and being more busy, not less
busy. (AGP23)
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Table 2 Practice conditions reported by GPs that might explain differences in practice
Situation in the UK Situation in Australia Differential effect on PSA testing
Prostate
screening culture
Doctors screening healthy people, or healthy
people demanding this, considered strange; ‘it
doesn’t happen. People don’t come in and say
“they feel fine, they just want all their blood
checks”…I don’t think the NHS could really do
that’ (GP21).
GPs report routinely offering (and encouraging)
patients to have multiple tests, perhaps including
PSA; healthy patients request health checks
regularly. Some considered this ‘normal’ and/or
‘responsible’.
‘Screening culture’ likely influences default
screening practices; in Australia PSA has
“become a fairly entrenched part of the male
[annual] health check up” (AGP17).
GP training UK GPs felt trained to avoid PSA testing, a
‘really big topic’ and ‘classic case’ in medical
exams and training. “The training that we
received is … how you would have a discussion
… when we’re asked for [the test], and you
almost felt like they were sort of trying to
dissuade asymptomatic men from having it…
that was definitely the sort of slant” (GP16).
GPs in Australia did not comment much about
their medical training and PSA testing; one GP
who did said “it’s one of the areas where it’s pretty
much self-taught and you develop your own
opinion” (AGP4).
GPs in the UK are specifically trained how to
advise asymptomatic men against screening,
so seem likely to have more skills to do so, and
to default to this practice.
Funding models UK GPs spaced appointments to allow for
appropriate care, because “the expectation from
the UK government as purchasers of the care
would be that [men] be counselled around the
limitations” (GP15). They were acutely aware of
“a responsibility [for] spending the finite [NHS]
resources” (GP23). UK GPs and practices did
not gain financially from test-ordering.
Conversely: PSA testing “just creates more
work” (GP6).
Some Australian GPs had systems to shorten
consultations about PSA testing, for example,
including PSA in routine bloodwork/‘bucket
testing’, automatic recall so patients could be
tested without seeing the GP. Some GPs blamed
Australia’s fee-for-service health system, which
encouraged seeing (and testing) more patients:“it
feeds itself to making more diagnoses” (AGP23).
The Australian fee-for-service funding model
incentivises [over]servicing; the UK’s NHS
scarce resources model incentivises caution in
creating burden on a limited system.
Guidelines UK GPs saw NICE guideline (a clear policy
directive) as authoritative, trustworthy, impartial
advice against testing; the national guideline
influenced practice. “I think people are wary of
practicing not in line with that and then they
have potential then for criticism” (GP3). The
established norm is structured communication
with men who ask about testing, using a written
information resource.
GPs found Australia’s competitive information
environment about PSA testing hard to navigate:
“there’s plenty of guidelines, but they’re all
different and there’s nothing official…there’s no
hard and fast rule” (AGP9). “It’s a very tricky area
because…opinion is divided depending on who
you talk to” (AGP20). Many GPs did not use a
guideline, citing patient demand, lack of time,
unfamiliarity or a preference for their own
judgement; some said RACGP guidance was an
unclear ‘cop-out’.
Having one authoritative guideline seems to
encourage consistent practice. At the time of
this study, such guidance did not exist in
Australia, probably contributing to variation in
PSA testing practice.17
Mass media and
public profile
UK GPs reported that prostate cancer is
sometimes in the news media but is “certainly
not something which is on the front page of
newspapers everyday” (GP8) and “doesn’t
translate into a lot of men coming and asking
Australian GPs said “there has been a lot of
media attention to PSA testing over the years”
(AGP15), a “part of the big problem with the
prostate cancer stuff” (AGP23). Requests
increased after media coverage;
Conflicting messages and promotion of PSA
testing in Australia drives demand from
patients; this is absent in the UK.
Continued
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Table 2 Continued
Situation in the UK Situation in Australia Differential effect on PSA testing
for PSA tests” (GP1). Many said patients would
only hear about PSA testing from their doctor.
‘media-influenced’ patients had preconceived
ideas, assuming screening was widely endorsed if
sanctioned on TV, “so they see it as their right to
have it” (AGP15). “Men know that it’s available…
so it’s hard not to bring it up” (AGP2).
Practice protocols All GPs within a single practice in the UK
tended to test in a similar way: they “practice as
a group and with group support” (GP20). This
occurred via ‘verbal agreement’ rather than
formal written protocols. Internal practice
protocols sometimes permitted practice nurses
to PSA-test asymptomatic men without GP
involvement.
In the absence of Australian consensus
guidelines, GPs developed their own testing
protocol over years, “I have built up my own idea
of practice” (AGP36). Practices need not have
formal protocols as “it is a judgement call at the
moment” (AGP39).
Presence or absence of protocols at practice
level does not seem to explain differences
between the two countries: both lacked
protocols.
Method of
screening
When UK GPs screened (rarely) they often did
DRE before or instead of PSA. They thought
DRE good or standard practice, and valued the
information it provided: “the two tests go
together” (GP14), “it’s a two-part process”
(GP23), “doing a PSA alone is worse than
doing nothing at all” (GP7). UK urologists
reportedly expect GPs to do DRE (although
urologists will repeat it).
Australian GPs reported rarely doing DRE in
asymptomatic men. Australian GPs were unsure
they could detect abnormality via DRE.
In the UK, DRE was used prior to or instead of
PSA, but was not recommended; conversely,
until recently Australian guidelines
recommended DRE with PSA but it was rarely
done.
Referral systems
for men with
abnormal results
In the UK, referral pathways following particular
test results are well defined: if PSA was
abnormal, GPs would always refer to NHS
urology to see the next available (possibly
unnamed) consultant, entirely publicly funded.
GPs’ cancer referrals were audited and GPs
made accountable for referrals.
After abnormal PSA test results, Australian GPs
varied greatly in when, how and to whom they
referred. In urban Australia, where there were
more urologists, immediate referral after abnormal
PSA was common; in rural Australia (fewer
urologists) GPs managed abnormal PSA tests for
months or years before referral. Australian
urologists may be seen publicly or privately;
private urology is a competitive marketplace.
Australia lacked a clear referral pathway for
PSA testing, so decisions were made by
individual GPs and patients, influenced by a
business model of healthcare and a private
health sector. In the UK, referral was
streamlined and publicly funded.
Position taken by
urology as a
profession
UK GPs said urologists “certainly do not push
us to screen men who are otherwise well—if
you asked any of them they’ll probably say it’s
actively discouraged” (GP1). (While not
reported by these GPs, we know anecdotally
and from the literature that some UK urologists
have advocated PSA screening.) GPs
described close communication and ‘strong
Australian GPs said urologists “encouraged PSAs
to be done a lot more urgently” (AGP37). Some
GPs accepted this advice; others “politely ignore
[d] the advice from urologists in that respect. And
from their organizations” (AGP19), as “they have
made life very difficult because they’re being very
unfair on the evidence that’s out there” (AGP18).
In rural areas, fly-in urologists ran monthly clinics,
and influential seminars encouraging testing.
There was strong variation in GP perceptions
and collaborations with urologists, within and
between countries. Some Australian GPs were
strongly sceptical of some urologists’ position;
UK GPs were less sceptical.
Continued
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UK GPs reported that the focus of the UK capitation
system is on quality of care rather than quantity of care.
They described processes in place to support GPs to
provide detailed evidence-based information to men
who ask about prostate screening; “What happens is you
type it [PSA] in and because we have web-based patient data
systems, they link…to the patient information stuff, so you tend
to use what comes to hand very easily…and because it’s
online…it’s as up to date as it can possibly be” (GP28).
Appointments about PSA testing in the UK are (or can
be) a two-step process; a ‘cooling-off period’ is built into
usual practice. A policy environment that encourages a
two-step process serves to avoid overuse and to ensure
decisions are well informed. The UK system looked to
be built on an underlying assumption that men who
know the facts about PSA testing are less likely to want
it. UK GPs reported “feeling quite supported over what we
are doing” (GP28) and seemed inclined to operate within
the bounds of their health system, while Australian GPs
often practiced according to individual standards.
In the UK, referral pathways following particular test
results are well deﬁned. GPs reported that the urology
departments in their local hospitals had issued referral
guidelines for GPs. These were often simpliﬁed versions
of The National Institute for Health and Care
Excellence (NICE) guidance and were seen as prescrip-
tive: as one GP said, “it’s a very clear path, it’s not a clinical
decision” (GP2). Most patients with abnormal PSA results
in the UK are referred to a National Health Service
(NHS) urology team and see the next available consult-
ant initially on an unnamed basis. It is publicly funded
(there are some private urologists, but they are a minor-
ity). These urologists therefore do not compete with one
another for business to any great extent.
Urologists in Australia serve the public and private
sectors: patients can be seen privately or as public outpa-
tients, and private urology, in particular, is a competitive
marketplace. The GPs who participated in this study
often spoke of patients as consumers, who maintained
substantial individual choice in healthcare decisions.
Australian GPs reported selecting (with or without the
patient) which individual, named urologist a patient will
see. They described making this choice based on factors
including the ‘personalities’ of the patient and urologist,
and how ‘interventionist’ they perceived the urologist to
be. The GPs varied greatly in when, how and to which
specialist they referred abnormal PSA test results. Men
could thus potentially receive very different care
depending on their GPs approach to PSA testing and
urology referral.
GPs appear to rely on different kinds of knowledge in
determining their practice
Accountability, clear expectations set in central policy
and support to apply best available evidence meant that
UK GPs were equipped to practice in a relatively predict-
able and standardised way, including when directly asked
about PSA testing by their patients. A number of GPs
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from the UK commented throughout the interviews that
they had never before reﬂected on why they approach
consultations about PSA testing in the way that they
described. They had never really had to grapple with
what to do as in regular practice they could conﬁdently
follow the available authoritative, evidence-based
guidance.
Many GPs in Australia also aimed to practice EBM by
following a published guideline. However, there was a
proportion who were more likely to practice according
to a different idea of evidence: for whom the ‘evidence’
from their own experience or the experiences of collea-
gues was critically important in directing their approach
to PSA testing. In the Australian context, ambiguity and
contestability surround interpretations of the evidence,21
and are accompanied by vague professional guidance.
Some GPs described research-based directives as incom-
patible with their day-to-day practice and preferred to
deal with what they described as routine cases using
their own experience. We reﬂect on these issues further
in the Discussion.
DISCUSSION
Australia and the UK draw on the same evidence base
for prostate cancer screening. The PSA test is in prin-
ciple available free to eligible men in both countries,
and prostate cancer mortality is roughly equivalent. Yet,
the rates of PSA testing for prostate cancer risk in the
two countries are strikingly different. We identiﬁed fun-
damental differences in how PSA testing occurred and
linked this to considerations of how testing was orga-
nised. Both countries have factors within their structural
and organisational environments that seem to reinforce
each other in inﬂuencing practice in a particular direc-
tion. This combination of multiple factors appears to
explain the very different testing and incidence rates,
serving mostly to drive more PSA testing in Australia and
less PSA testing in the UK.
Australians have been shown empirically to have atti-
tudes broadly in favour of cancer screening.22 The
Australian media has been shown empirically to deliver
a generally pro-PSA-screening message.23 These two
combined seem likely to increase rather than limit
patient demand for PSA testing, and thus to promote
rather than retract a market for screening. A
fee-for-service payment system allows Australian GPs sig-
niﬁcant scope to routinely offer PSA testing, and gives
them a ﬁnancial incentive to provide this service to ﬁll
the demands of the market. Mixed messages in the
current Australian guidelines and some specialists pub-
licly advocating for PSA testing do little to curtail use of
the PSA test. In comparison, the medical training of GPs
in the UK to avoid PSA testing, strong discouragement
from the NHS, little patient demand, limited healthcare
resources, and zero ﬁnancial gains from screening for
Figure 1 Direction in which system factors described in table 2 drive PSA testing in Australia (black) and the UK (grey). Upward
arrows indicate drivers towards more PSA testing, downward arrows indicate drivers towards lower rates of PSA testing, circles
indicate neutral factors with no reported impact. PSA, prostate-specific antigen.
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GPs and public sector urologists were reﬂected in the
GPs’ explanations of low rates of testing in their respect-
ive practices.
What is being done in Australia to address divergent use
of the PSA test?
The provision of and access to PSA testing in Australia is
currently extremely heterogeneous, partly dependent on
the reasoning and preferences of individual doctors.
Newly released national evidence-based clinical guide-
lines aim to drive greater consistency in testing prac-
tices.24 The consensus guidelines, which include an
‘after the test’ component, may prompt more evidence-
based discussions and streamlined delivery of consistent
information, and standardise referral pathways in
Australia.
The authoritative consensus guidelines are a signiﬁ-
cant move in the right direction for ‘smarter screen-
ing’25 in Australia. An accompanying decision aid is
being designed to provide an opportunity to make more
informed decisions. Yet, the other drivers of screening
remain in the Australian setting compared with the UK
where PSA screening is discouraged at a system-wide
level. The Australian guidance has focused attention pri-
marily on prioritising individual choice. While the new
NHMRC guidelines represent a ﬁrst step in addressing
inconsistencies in what GPs are advised to do, and will
be a useful information resource to incorporate into
evidence-based discussions; they may not sufﬁce to
address what is arguably the most important objective:
to reduce unnecessary or harmful prostate screening.
Although reducing PSA testing rates in Australia is not
an explicitly agreed goal of the new NHMRC guidelines,
the comparable death rates despite considerably less
screening suggest it is likely that the lower rates of PSA
testing under the UK system are preferable. In the fol-
lowing section, we suggest areas for consideration and
evaluation (alongside the NHMRC guidelines), which
may potentially decrease use of the PSA test for screen-
ing purposes in Australian primary care.
What can be done in Australia to improve screening
practice?
By comparing Australia with the UK, we have identiﬁed
features of the context in which screening options are
offered that might not otherwise have been appreciated
as signiﬁcant in the Australian setting. Overall,
Australian men have fewer practical barriers to undergo-
ing a PSA test, alongside higher incentives for GPs to
perform the test. We suggest that, if reducing the rate of
PSA testing is a reasonable goal for Australian general
practice, the following strategies (structural and organ-
isational) may assist in achieving that goal.
Two-step consultations: Information provision that is sep-
arate from PSA testing availability via ‘staggered’
appointments, which incorporate a cooling-off period.
Tambor et al26 reported that when testing could be
obtained conveniently as ‘part of a battery of other tests’
approach as used in the Australian context, uptake was
considerably higher than when additional effort was
required to have a test.
Incentivise informed shared decision-making (SDM), as the
USA has introduced for lung cancer screening, for
example.27 UK GPs do not receive reimbursement spe-
ciﬁcally for engaging in SDM with patients; however,
they are accountable for their screening activity and use
of NHS resources. GPs in Australia may initially need
ﬁnancial encouragement to implement the NHMRC
guidance (provide information rather than offering
screening) if this is in contrast to their usual practice.
Australia’s fee-for-service GP payment system rewards
activity in primary care, such as testing, rather than the
giving of information to permit an informed choice
about whether to test.
Fund PSA testing differently: In the USA, Medicare has
considered imposing a penalty for physicians who
perform ‘non-recommended’ prostate cancer screening
with the PSA test as part of a federal effort towards value-
based care.28 Financial disincentives for GPs and men
over time will potentially diminish harm caused by
unnecessary screening (eg, of low-risk men or men with
a limited life expectancy), as a ﬁnancial barrier may
result in more considered decisions on the part of men
and their doctor. However, an ongoing and relevant
counterargument is that doctors should not be rewarded
for withholding a test that could help some men, nor
restrict the options of men with limited ﬁnancial means.
Welch and others have suggested introducing a small
cost to men for PSA testing.29 Introducing a small cost
for a PSA test with clearly communicated exceptions
(eg, men with strong risk factors for prostate cancer)
may be a reasonable option in Australia. There are plans
in Australia to consider changes to the Medicare Beneﬁts
Schedule item number to align with the new PSA testing
guidelines and only allow coverage for a PSA test every
second year, rather than annually. However, the PSA test
is currently in principle available free to men in Australia
and the UK, suggesting cost may not be a key factor
inﬂuencing more frequent testing in Australia. This
would be a pertinent topic for further research.
Why might achieving a shift in GP practice be difficult?
Although the varied structural and organisational condi-
tions in the respective healthcare systems of Australia
and the UK seemed to explain much of the difference
in GP accounts of their PSA testing practice—at the
patient and consultation level—another layer to the
decision-making environment was also evident. Gabbay
and le May’s theory of ‘mindlines’ is particularly relevant
to our analysis. We hypothesise from our data that GPs
from Australia and the UK are following different ‘mind-
lines’, shaped by their respective cultures, contexts and
experiential knowledge.
We propose that UK GPs have internalised an organ-
isationally embedded consistent mindline, based on
the evidence-based recommendations from a trusted
10 Pickles K, et al. BMJ Open 2016;6:e011932. doi:10.1136/bmjopen-2016-011932
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authoritative voice. All GPs appeared to agree about
what practice was appropriate, implementing a relatively
similar version of evidence-based practice. There was
less room to move in their individual interpretations of
the evidence because the professional guidance was con-
sistent and not contested—UK GPs were advised which
evidence was appropriate, and provided with supporting
materials to distribute to men. Funding arrangements
also put explicit boundaries around what is considered
acceptable practice. The mindline used by UK GPs
seems to have developed during their training and was
subsequently collectively shared and reinforced via reli-
able professional networks, including urologists. It was
rarely challenged because of clear communication, a col-
lective understanding of requirements and expectations,
and limited exposure to men requesting prostate
screening.
We suggest that, in contrast to the UK, GPs in
Australia are accustomed to a noisy marketplace of con-
ﬂicting advice, including from urologists. As a result,
their mindlines appear to be more independently con-
structed based on individual experiences, and strongly
inﬂuenced by contextual considerations. Like the UK
GPs, the Australian GPs’ mindlines were developed and
reinforced via similar processes of experience, repetition
and interactions, but these occurred within local circum-
stances and macro systems that looked very different to
the UK situation. It is likely that Australian GPs’ mind-
lines vary considerably from one GP to the next as they
navigate and interpret the changeable conditions.
Australian GPs described a broad spectrum of men regu-
larly asking about PSA screening, each with very differ-
ent expectations. So, while an individual Australian GP
may have a relatively uniﬁed approach to PSA screening
decisions and discussions, speciﬁc contexts and patient
presentations could prompt temporary deviation from
this mindline in favour of an alternative.
While producing guidelines (such as the NHMRC
guideline) as a formal source of knowledge is essential,
against a background of clinicians’ diverse ingrained
habits and history, guidelines are unlikely to be enough
to alter established clinical practice in Australian GPs.
Nonetheless, consistent guidelines provide a much
needed foundation to build on. As Gabbay and le May
conclude, practitioners have a collective responsibility to
ensure their mindlines are based on research evidence
wherever possible,15 and the NHMRC guidelines provide
a consensus regarding the appropriate evidence base.
However, above all, our research has demonstrated the
overwhelming inﬂuence of local contexts on clinical
practice. GPs’ established mindlines and rules of thumb
appear to interact with the social and organisational
context. If policy leaders want to promote practice con-
sistent with the consensus guidelines, they are likely to
need to work actively, alongside providing ongoing
support for GPs, in directing how the NHMRC guide-
lines are received, implemented and used in practice.
The process should prioritise establishing GPs’ trust in
the guidelines as a reliable source of information for
supporting modiﬁed practice patterns among those
whose practice is not aligned with the new recommenda-
tions. Our ﬁndings and Gabbay and le May’s theory
suggest that guideline dissemination might be best tar-
geted through favoured sources of information, includ-
ing inﬂuential GP and specialist colleagues—although
conﬂicts of interest might make this challenging.
Future research might usefully explore the likelihood
and feasibility of a cultural shift around PSA screening,
examining men’s and broader public enthusiasm to screen
in Australia. Schwartz et al30 found that the majority of
American men they sampled would over-rule their physi-
cian’s recommendations for less frequent or no screening.
A closer look at urologists’ ‘mindlines’ may also be rele-
vant, as these appear to inﬂuence the mindlines of GPs.
Limitations
We interviewed a large number of highly informa-
tive participants (GPs) with diverse opinions and ap-
proaches; participation in the study was self-selecting. It
is possible that physicians with particularly strong opi-
nions about prostate cancer screening were more likely
to volunteer.
CONCLUSION
Important drivers of prostate cancer screening are
evident at a number of levels. PSA testing rates arise
from more than individual GP attitudes towards screen-
ing: current and historical structures, systems and rules
all play a signiﬁcant role in creating the mindlines that
GPs employ in their practice. It is likely that all of these
inﬂuences will need to be addressed if these mindlines,
and thus practice, are to change.
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